News
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...
BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...
Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback